These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 17762241)
21. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Falagas ME; Rafailidis PI; Matthaiou DK; Virtzili S; Nikita D; Michalopoulos A Int J Antimicrob Agents; 2008 Nov; 32(5):450-4. PubMed ID: 18768302 [TBL] [Abstract][Full Text] [Related]
22. The current state of multidrug-resistant gram-negative bacilli in North America. Nicasio AM; Kuti JL; Nicolau DP Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969 [TBL] [Abstract][Full Text] [Related]
23. When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach. Falagas ME; Rafailidis PI Shock; 2007 Jun; 27(6):605-9. PubMed ID: 17505298 [TBL] [Abstract][Full Text] [Related]
24. Resistance to antibiotics: are we in the post-antibiotic era? Alanis AJ Arch Med Res; 2005; 36(6):697-705. PubMed ID: 16216651 [TBL] [Abstract][Full Text] [Related]
26. Update on the treatment of Pseudomonas aeruginosa pneumonia. El Solh AA; Alhajhusain A J Antimicrob Chemother; 2009 Aug; 64(2):229-38. PubMed ID: 19520717 [TBL] [Abstract][Full Text] [Related]
27. The role of gram-negative bacteria in healthcare-associated pneumonia. Restrepo MI; Anzueto A Semin Respir Crit Care Med; 2009 Feb; 30(1):61-6. PubMed ID: 19199188 [TBL] [Abstract][Full Text] [Related]
28. Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. Roberts JA; Webb SA; Lipman J Int J Antimicrob Agents; 2007 Feb; 29(2):117-28. PubMed ID: 17158033 [TBL] [Abstract][Full Text] [Related]
29. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Niederman MS Clin Infect Dis; 2006 Jan; 42 Suppl 2():S72-81. PubMed ID: 16355320 [TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989 [TBL] [Abstract][Full Text] [Related]
31. New antibiotic agents for bloodstream infections. Vergidis PI; Falagas ME Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329 [TBL] [Abstract][Full Text] [Related]
32. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics]. Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430 [TBL] [Abstract][Full Text] [Related]
33. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Falagas ME; Kasiakou SK; Tsiodras S; Michalopoulos A Clin Med Res; 2006 Jun; 4(2):138-46. PubMed ID: 16809407 [TBL] [Abstract][Full Text] [Related]
34. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205 [TBL] [Abstract][Full Text] [Related]
35. Polymyxin antibiotics for gram-negative infections. Arnold TM; Forrest GN; Messmer KJ Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197 [TBL] [Abstract][Full Text] [Related]